Inhibition of proliferation and expression of AR/PSA by herbal supplement equiguard™ in LNcAP cells cultured in androgen-proficient FBS and androgen-deficient charcoal-stripped FBS is correlated with increased serine-15 phosphorylation of the tumor suppressor gene p53

Anticancer Research

Volumn 23, Issue 3 B, 2003, Pages 2489-2498

  Lu, Xiaohua ^a   Guo, Junqiao ^a   Hsieh, Tze Chen ^a   Wu, Joseph M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Androgen receptor (AR); Charcoal stripped FBS; Equiguard ; LNCaP cells; Prostate specific antigen (PSA)

Indexed keywords

AMINO ACID; ANDROGEN RECEPTOR; CHINESE DRUG; CYCLINE; EQUIGUARD; HERBACEOUS AGENT; LIGUSTRUM LUCIDUM EXTRACT; PLANT EXTRACT; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; SCHISANDRA CHINENSIS EXTRACT; SERINE;

ARTICLE; ASTRAGALUS MEMBRANACEUS; BAILL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CUSCUTA CHINENSIS; DIET SUPPLEMENTATION; DRUG CAPSULE; DRUG FORMULATION; DRUG MANUFACTURE; EPIMEDIUM BREVICOMUM; FRUIT; GENE EXPRESSION; HERB; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIGUSTRUM LUCIDUM; MALE; MEDICINAL PLANT; MORINDA OFFICINALIS HOW; PLANT LEAF; PLANT ROOT; PLANT STEM; POLYACRYLAMIDE GEL ELECTROPHORESIS; POWDER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PSORALEA CORYLIFOLIA; QUALITY CONTROL; ROSA LAEVIGATA MICHX; RUBUS CHINGII HU; SCHISANDRA CHINENSIS; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

CHARCOAL; CULTURE MEDIA; DRUGS, CHINESE HERBAL; GENE EXPRESSION; GROWTH INHIBITORS; HUMANS; MALE; PHOSPHORYLATION; PHYTOTHERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SERINE; TUMOR CELLS, CULTURED; TUMOR STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0042306527     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
2. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin 50: 7-33, 2000.
3. Doll R and Peto R: The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Canc Inst 66: 1191-1308, 1981.
4. Parkin DM and Muir CS: Cancer incidence in five continents. IARC Sci Publ 120: 45-173, 1992.
5. Sheehan DM: Herbal medicines, phytoestrogens and toxicity: risk: benefit considerations. Proc Soc Exp Biol Med 217: 379-385, 1998.
6. Harvey AL: Pharmaceuticals and agrochemicals. In: Drugs from Natural Products (Harvey AL ed.) Chichester, Ellis Horwood, 1993.
7. Yang CS, Landau JM, Huang MT and Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compounds. Ann Rev Nutr 21: 381-406, 2001.
8. Gescher AJ, Sharma RA and Steward WP: Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncology 2: 371-379, 2001.
9. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM and Von Hoff DD: Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Canc Res 8: 314-346, 2002.
10. Sporn MB and Suh N: Chemoprevention of cancer. Carcinogenesis 21: 525-530, 2000.
11. Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L and Zhu Z: Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res 61: 7002-7008, 2001.
12. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS and Menard S: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13: 65-72, 2002.
13. Power BE, Kortt AA and Hudson PJ: Generation of recombinant multimeric antibody fragments for tumor diagnosis and therapy. Methods Mol Biol 207: 335-350, 2003.
14. Hsieh TC, Lu X, Guo J, Xiong W, Kunicki J, Darzynkiewicz Z and Wu JM: Effects of herbal preparation Equiguard™ on hormone-responsive and hormone-refractory prostate cancer cells. Mechanistic studies. Int J Oncol 20: 681-689, 2002.
15. Hsieh TC, Traganos F, Darzynkiewicz Z and Wu JM: Effects of PC-SPES on proliferation and expression of AR/PSA in androgen responsive LNCaP cells are independent of estradiol. Anticancer Res 22: 2051-2060, 2002.
16. Hsieh TC, Chen SS, Wang X and Wu JM: Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem Mol Biol Int 42: 535-544, 1997.
17. DiPietrantonio A, Hsieh TC, Olson SC and Wu JM: Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinamide (4HPR). Int J Canc 78: 53-61, 1998.
18. Hsieh TC and Wu JM: Changes in cell growth, cyclin/kinase, endogenous phosphoproteins and nm23 gene expression in human prostatic JCA-1 cells treated with modified citrus pectin. Biochem Mol Biol 37: 833-841, 1995.
19. 3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Commun 223: 141-146, 1996.
20. Hsieh TC and Wu JM: Effects of the retinoid 4-HPR on human prostate growth, induction of apoptosis and modulation of androgen receptor (AR) and prostate specific antigen (PSA) expression. Prostate 33: 97-104, 1997.
21. Hsieh TC and Wu JM: Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249: 109-115, 1999.
22. Saeed B, Zhang H and Ng SC: Apoptotic program is initiated but not completed in LNCaP cells in response to growth in charcoal-stripped media. Prostate 31: 145-152, 1997.
23. Murillo H, Huang H, Schmidt LJ, Smith DI and Tindall DJ: Role of PI3K signaling in survival and progression of LNCaP cancer cells to the androgen refractory state. Endocrinol 142: 4795-4805, 2001.
24. Von Hoff DD: He's not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 82: 96-101, 1990.
25. Courtenay VD and Mills J: An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents. Br J Cancer 37: 261-268, 1978.
26. Bellamy WT: Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs 44: 690-708, 1992.
27. Von Hoff DD, Sandbach JF, Clark GM, Turner JN, Forseth BF, Piccart MJ, Colombo N and Muggia FM: Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 82: 110-116, 1990
28. Hanauske AR and Von Hoff DD: In vitro and in vivo predictive tests. In: Cancer Medicine (Holland JF ed). Williams and Wilkins, pp 869-874, 1997.
29. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S and Chung LW: LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44: 91-103, 2000.
30. Kokontis JM, Hay N and Liao S: Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-953, 1998.
31. Kirschenbaum A, Ren M and Levine AC: Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line. Steroids 58: 439-444, 1993.
32. Yang Y, Chisholm GD and Habib FK: The distribution of PSA, cathepsin-D, and pS2 in BPH and cancer of the prostate. Prostate 21: 201-208, 1992.
33. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson P-A, Stenman U-H, Dowell B, Lovgren T and Lilja H: Free, complex and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154: 1090-1095, 1995.
34. Stege R, Grande M, Carlstrom K, Tribukait B and Pousette A: Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Canc Res 6: 160-165, 2000.
35. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, Evans CL, Gasior CL, Linton HJ, Carpenter P and Rittenhouse HG: A truncated form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61: 6958-6963, 2001.
36. Dixon SC, Knopf KB and Figg WD: The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 53: 73-91, 2001.
37. Cunha GR, Donjancour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ and Sugimua Y: The endocrinology and developmental biology of the prostate. Endocrinol Rev 8: 338-362, 1987.
38. Chen CD and Sawyers CL: NF-κB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 22: 2862-2870, 2002.
39. Debes JD, Schmidt LJ, Huang H and Tindall DJ: p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Canc Res 62: 5632-5636, 2002.
40. Ueda T, Mawji N, Bruchovsky N and Sadar MD: Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277: 38087-38094, 2002.
41. Isaacs WB, Carter BS and Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Canc Res 51: 4716-4720, 1991.
42. Lin HY, Shih A, Davis FB, Tang HY, Martino LJ, Bennett JA and Davis PJ: Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol 168: 748-55, 2002.
43. Gupta S, Ahmad N, Nieminen AL and Mukhtar H: Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 164: 82-90, 2000.
44. Kobayashi T, Nakata T and Kuzumaki T: Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett 176: 17-23, 2002.
45. Ljungman M: Dial 9-1-1 for p53: mechanism of p53 activation by cellular stress. Neoplasia 2: 208-225, 2000.
46. Nakagawa T, Taya Y, Tamai K and Yamaizumi M: Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-stranded break. Mol Cell Biol 19: 2828-2834, 1999.
47. Dumaz N and Meek DW: Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with MDM2. EMBO J 18: 7002-7010, 1999.
48. Blagosklonny MV: p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effects. FASEB J 14: 1901-1907, 2000.
49. Ikezoe T, Chen SS, Heber D, Taguchi H and Koeffler HP: Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 49: 285-292, 2001.
50. Rafi MM, Rosen RT, Vassil A, Ho CT, Zhang H, Ghai G, Lambert G and DiPaola RS: Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res 20: 2653-2658, 2000.
51. Watanabe M, Hayakawa S, Isemura M, Kumazawa S, Nakayama T, Mori C and Kawakami T: Identification of licocoumarone as an apoptosis-inducing component in licorice. Biol Pharm Bull 25: 1388-1390, 2002.
52. Kitano M, Wanibuchi H, Kikuzaki H, Nakatani N, Imaoka S, Funae Y, Hayashi S and Fukushima S: Chemopreventive effects of coumaperine from pepper on the initiation stage of chemical hepatocarcinogenesis in the rat. Jpn J Cancer Res 91: 674-680, 2000.
53. Diamandis EP: Prostate-specific antigen: A cancer fighter and a valuable messenger? Clin Chem 26: 896-900, 2000.
54. Wang LG, Liu XM, Kreis W and Budman DR: Involvement of prostate specific antigen in the stimulation of LNCaP cell growth. Oncol Rep 3: 911-917, 1996.
55. Sutkowski DM, Goode RL, Baniel J, Teater C, Cohen P, McNulty AM, Hsiung HM, Becker GW and Neebauer BL: Growth regulation of prostate stromal cells by prostate-specific antigen. J Natl Cancer Inst 91: 1663-1669, 1999.
56. Cohen P, Graves HCB, Peehl DM, Kamarei M, Guidice LC and Rosenfeld RG: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 73: 401-407, 1991.
57. Iwamura M, Hellman J, Cockett ATK, Lilja H and Gershagen S: Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urol 48: 317-325, 1996.
58. Cramer SD, Chen Z and Peehl DM: Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: Inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 156: 526-531, 1996.
59. Fortier AH, Nelson BJ, Grella DK and Holaday JW: Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 91: 1635-1640, 1999.
60. Yonou H, Aoyagi Y, Kanomata N, Kamijo T, Oda T, Yokose T, Hasebe T, Nagai K, Hatano T, Ogawa Y and Ochiai A: Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem Biophys Res Commun 289: 1082-1087, 2001.
61. Sun X-Y, Donald SP and Phang JM: Trestosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 22: 1775-1780, 2001.
62. Jenster G: The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 26: 407-421, 1999.
63. Balk SP: Androgen receptor as a target in androgen-independent prostate cancer. Urol 60 (3 Suppl) 1: 132-138, 2002.
64. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM and Feldman D: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6: 703-706, 2000.
65. Yeh S, Miyamoto H, Shima H and Chang C: From estrogen to androgen receptor: A new pathway for sex hormones in prostate. Proc Natl Acad Sci USA 95: 5527-5532, 1998.
66. Maggiolini M, Vivacqua A, Carpino A, Bonofiglio D, Fasanella G, Salerno M, Picard D and Ando S: The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells. Mol Pharmacol 62: 1027-1035, 2002.
67. Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G and Chang C: Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res 62: 6039-6044, 2002.
68. Rokhlin OW, Gudkov AV, Kwek S, Glover RA, Gewies AS and Cohen MB: p53 is involved in tumor necrosis factor-alpha-induced apoptosis in the human prostatic carcinoma cell line LNCaP. Oncogene 19: 1959-1968, 2000.
69. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI and Cordon-Carlo C: Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression. Clin Cancer Res 5: 2082-2088, 1999.
70. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU and Cox JD: p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 89: 158-65, 1997.
71. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH and deVere White RW: Complex functions of mutant p53 alleles from human prostate cancer. Prostate 51: 59-72, 2002.
72. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D and Yang G: Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 10: 869-879, 1995.
73. Thompson TC, Timme TL, Park SH, Yang G, Ren C: Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease. Prostate 43: 248-54, 2000.
74. Kishi H, Nakagawa K, Matsumoto M, Suga M, Ando M, Taya Y and Yamaizumi M: Osmotic shock induces G1 arrest through p53 phosphorylation at Ser33 by activated p38MAPK without phosphorylation at Ser15 and Ser20. J Biol Chem 276: 39115-39122, 2001.